(i) Highest levels of EphA2 staining in prostatic adenocarcinoma followed by high grade intraepithelial neoplasia with low positive EphA2 staining in benign tissue (ii) EphA2 stimulation with ephrin-A1 resulted in inhibition of PC3 migration
(i) Increase level of EphA3 in androgen independent prostate cancer cells compared to androgen dependent prostate cancer cells (ii) Inactivation of AMP-activated protein kinase (AMPK) resulted in transformation of prostate cancer cell line and upregulation of EphA3 mRNA
(i) cDNA microarray shows EphA4 elevation in prostatic intraepithelial neoplasia and prostate cancer (1) SiRNA knockout of EphA4 resulted in decrease cell viability and colony formation (ii) EphA4 stimulation with ephrin-A5 resulted in inhibition of PC3 migration (iii) EphA4 may be regulated by ERBB3/HER3 (1) Knockdown of ERBB3 in DU-145 resulted in downregulation of EphA4
Mutant expression of inactive EphB2 in prostate cancer
(i) Two mutations in extracellular part of EphB2 and six mutations in the intracellular part of EphB2 (1) Extracellular mutation: R199H, A279S (2) Intracellular mutation: D679N, 2139+2T→C, Q723X, T909M, K1019X, and 3051delA (ii) Loss of EphB2 in primary prostate tumor cells compared to normal prostate epithelium cells
(i) Proteomic analysis of LnCaP cell culture media demonstrated increased levels of ephrin-A5 post androgen exposure (ii) Lower levels of ephin-A5 correlated with shorter predicated survival time